广泛中和抗体治疗在博茨瓦纳具有有利储存库特征的儿童中维持HIV抑制
在博茨瓦纳开展的前瞻性临床试验纳入25名出生7天内启动小分子抗逆转录病毒治疗(ART)并持续治疗至少96周的HIV-1感染儿童,评估两种广泛中和抗体(VRC01LS和10-1074)每4周静脉给药替代ART的效果。11名(44%)儿童在仅用抗体治疗24周内维持HIV-1 RNA低于400拷贝/毫升;14名(56%)在中位4周时出现高于400拷贝/毫升的可检测病毒血症。对10-1074敏感的储存HIV-1前病毒、较低出生时外周血单核细胞HIV-1 DNA储存库、早期持续病毒抑制及入组时定性HIV-1 DNA PCR和HIV-1血清学双阴性,与单用抗体维持抑制相关。
要点
- 25名早期启动ART的HIV-1感染儿童接受VRC01LS和10-1074两种广泛中和抗体静脉给药。
- 11名(44%)儿童仅用抗体治疗24周内维持HIV-1 RNA低于400拷贝/毫升。
- 14名(56%)儿童在中位4周时出现高于400拷贝/毫升的可检测病毒血症。
核心结论
- 这项概念验证研究提示,广泛中和抗体可能代表婴幼儿和儿童HIV-1感染者的一种有前景的治疗方式。
- 未来需要使用具有更广覆盖度和更强效力的更新型广泛中和抗体组合开展研究。
研究设计与样本
- 前瞻性临床试验,纳入25名出生7天内已启动小分子ART并持续治疗至少96周的HIV-1感染儿童。
- 两种广泛中和抗体VRC01LS和10-1074均每4周静脉给药,与ART重叠至少8周,随后继续至多24周或直至无ART情况下HIV-1 RNA升至400拷贝/毫升以上。
主要发现
- 11名(44%)儿童在仅用广泛中和抗体治疗24周内维持HIV-1 RNA低于400拷贝/毫升。
- 14名(56%)儿童在中位4周时出现高于400拷贝/毫升的可检测病毒血症。
- 对10-1074敏感的储存HIV-1前病毒、较低出生时外周血单核细胞HIV-1 DNA储存库、早期持续病毒抑制及入组时定性HIV-1 DNA PCR和HIV-1血清学双阴性,与单用广泛中和抗体维持抑制相关。
局限性
- 原文指出未来需要使用具有更广覆盖度和更强效力的更新型广泛中和抗体组合开展研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Broadly neutralizing antibodies (bNAbs) may provide an alternative to standard antiretroviral treatment (ART) for controlling HIV-1 replication and may have immunotherapeutic effects against HIV-1 reservoirs. We conducted a prospective clinical trial with two HIV-1 bNAbs (VRC01LS and 10-1074) in children (n = 25) who had previously initiated small-molecule ART treatment before 7 days of age and who continued treatment for at least 96 weeks. Both bNAbs were dosed intravenously every 4 weeks, overlapping with ART for at least 8 weeks and then continued for up to 24 weeks or until detectable viremia of HIV-1 RNA rose above 400 copies per milliliter in the absence of ART. Eleven (44%) children maintained HIV-1 RNA below 400 copies per milliliter through 24 weeks of bNAb-only treatment; 14 (56%) had detectable viremia above 400 copies per milliliter at a median of 4 weeks. Archived HIV-1 provirus susceptible to 10-1074, lower birth HIV-1 DNA reservoir in peripheral blood mononuclear cells, sustained viral suppression throughout early life, and combined negative qualitative HIV-1 DNA polymerase chain reaction and negative HIV-1 serology at entry were associated with maintaining suppression on bNAbs alone. This proof-of-concept study suggests that bNAbs may represent a promising treatment modality for infants and children living with HIV-1. Future studies using newer bNAb combinations with greater breadth and potency are warranted.
引用
- Shapiro RL, Ajibola G, Maswabi K, et al. Broadly neutralizing antibody treatment maintained HIV suppression in children with favorable reservoir characteristics in Botswana. Sci Transl Med. 2023. PMID: 37406137. doi:10.1126/scitranslmed.adh0004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。